SkQ1 Eye Composition for Cataract and Macular Dystrophy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eye pathologies such as cataract and macular degeneration, particularly age-related macular degeneration, are inadequate in effectively addressing oxidative stress and vision deterioration, with limited options available for prophylaxis and treatment beyond natural antioxidants like lutein, zeaxanthin, and vitamins E and C.
Innovation Solution
A pharmaceutical composition comprising a compound with a specific structure (I) that includes a targeting moiety, linker group, and antioxidant, specifically plastoquinone (SkQ1), which is administered to provide enhanced antioxidant protection and therapeutic benefits for eye pathologies, including macular degeneration and cataract, through various administration methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If natural antioxidants (lutein, zeaxanthin, vitamins E and C) are used for treating eye pathologies, then antioxidant protection is provided, but therapeutic effectiveness is insufficient and treatment options are limited
Solution Approach 1:
The patent employs composite antioxidant structures combining plastoquinone core with various side chains (hydroxyl, carboxyl, amino groups) and conjugation lengths to create a family of compounds with enhanced and diversified antioxidant activities for different eye pathologies
Solution Approach 2:
The patent systematically varies chemical parameters including side chain types, conjugation lengths, and substitution patterns of plastoquinone derivatives to optimize antioxidant potency and specificity for different eye conditions such as cataract, macular degeneration, and retinal dystrophy
2Duration of action of stationary object
If oxidative stress is addressed with antioxidants, then vision deterioration is slowed, but the complexity of formulating effective pharmaceutical compositions increases
Solution Approach 1:
The patent divides the antioxidant function into specific molecular components (plastoquinone core, side chains, conjugation systems) that can be independently optimized and combined to achieve desired therapeutic effects while managing formulation complexity
Solution Approach 2:
The plastoquinone structure acts as an intermediary molecule that bridges the gap between dietary antioxidants and therapeutic efficacy, providing enhanced bioavailability and targeted action in the eye while simplifying formulation requirements
Data Source
AI summary
The present invention relates to pharmacology, medicine, ophthalmology, and, in particular, concerns a class of chemical compounds of structure (I) and also their solvates, isomers or prodrugs applicable when incorporated into pharmaceutical compositions also containing pharmaceutically acceptable carrier which can be useful for prophylaxis and treatment of different eye pathologies such as cataract and macular dystrophy.